At the end of September 2019, the U.S. administration leaked to Bloomberg that it was discussing ways to limit Chinese company access to the U.S. capital markets. This leak was more substantive than the similar tweet made by President Trump in the summer, and included excessive and unlikely options such as "mass delisting" of all Chinese stocks. Changes in both regulatory control and exchange listing standards could have a profound impact on Chinese company IPOs planned for 2020 and beyond. Furthermore, already-listed Chinese companies face risks related to new regulation, greater enforcement, changing exchange listing standards, and depressed valuations.
To help Chinese companies navigate this shifting landscape, AmCham China is hosting a 2 hour panel/seminar in which key U.S. capital markets service providers will offer education, advice, and answer questions about these developments. Panelists are from investment banking, U.S. securities law, Big 4 audit, the stock exchange, investor relations, and an ADR depositary bank. The panelists are all senior executives or partners from American firms that assist Chinese companies to list in the U.S.
Board Member and Outbound Investment Chair at Amcham China
Managing Director, Co-Head of Asia ECM at Citi Bank
TMT Practice Partner at PwC
Managing Director of The Blueshirt Group Asia
WeWork, Pacific Century Place, Mandela Room
5F, Gate 5, Pacific Century Place, 2A Workers' Stadium North Road
Beijing, Chaoyang District, China
AmCham China New Office Map.jpg